Graham Parry's questions to Novartis AG (NVS) leadership • Q2 2024
Question
In a second question, Graham Parry from Bank of America asked if Novartis might need to revisit its peak sales guidance for Kesimpta given its strong performance, and inquired about its market penetration in the U.S. and rest of world.
Answer
CEO Vasant Narasimhan acknowledged the strong performance and internal debate about Kesimpta's ultimate potential, noting there is 'plenty of room to run' as B-cell inhibitors gain share. He mentioned the company is looking at the peak sales potential but will provide more precise guidance when ready. He also suggested the underwhelming data from BTK inhibitors could provide a further tailwind for Kesimpta's long-term growth.